Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heparin Effects on LPL and TG Levels in Healthy Participants
NCT05178550Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2021
- Primary completion
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of heparin (2 arms), sponsored by Novo Nordisk. Primary endpoints: Change from baseline in Lipoprotein Lipase (LPL) levels, Change from baseline in LPL activity and 1 more. Started Dec 2021; status: completed.
02
Drugs
heparin
Beyond the preview
Go deeper on NCT05178550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178550.